|24th February 2020||Vimal Mehta||300,000||Sale back to the issuer||$30.08||$9,024,000.00|
|24th February 2020||Krishnan Nandabalan||300,000||Sale back to the issuer||$30.08||$9,024,000.00|
|14th February 2020||Frank Yocca||80,000||Exercise of derivative||$0.41||$32,800.00|
|23rd August 2019||Peter Mueller||1,554||Open or private purchase||$9.34||$14,514.36|
|22nd August 2019||Peter Mueller||6,646||Open or private purchase||$8.83||$58,684.18|
|21st August 2019||Peter Mueller||1,800||Open or private purchase||$8.42||$15,156.00|
|16th August 2019||Vimal Mehta||974||Open or private purchase||$8.89||$8,658.86|
|15th August 2019||Vimal Mehta||2,625||Open or private purchase||$8.67||$22,758.75|
|14th August 2019||Vimal Mehta||358||Open or private purchase||$8.44||$3,021.52|
|13th August 2019||Frank Yocca||6,547||Open or private purchase||$8.67||$56,762.49|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.